Drug intelligence / Profile preview

20-valent pneumococcal conjugate vaccine + tozinameran

Development stage
Unknown
Lead developer
Pfizer
Modality
mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

This is a **combination vaccine** consisting of the **20-valent pneumococcal conjugate vaccine** (commonly known by the brand name **Prevnar 20**, which protects against 20 serotypes of *Streptococcus pneumoniae* by inducing antibody responses to bacterial polysaccharides conjugated to carrier proteins) and **tozinameran** (the active ingredient in **Comirnaty**, an mRNA-based COVID-19 vaccine encoding the SARS-CoV-2 spike protein to induce immunity against COVID-19)[1][4][6][9]. Each component acts through distinct mechanisms: the pneumococcal vaccine is a conjugate vaccine that activates the immune response against pneumococcal bacteria via T-cell dependent processes, while tozinameran provides protection against COVID-19 via induction of neutralizing antibodies and a cellular immune response against the spike protein.

02

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)SARS-CoV-2 spike

Beyond the preview

Go deeper on 20-valent pneumococcal conjugate vaccine + tozinameran.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 20-valent pneumococcal conjugate vaccine + tozinameran.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call